Immune Checkpoint Inhibitors in Acute Myeloid Leukemia: Novel Combinations and Therapeutic Targets

Overview

Journal Curr Oncol Rep

Publisher Current Science

Specialty Oncology

Date 2019 Mar 25

PMID 30904967

Citations 49

Authors

Maximilian Stahl

Aaron D Goldberg

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: Immune checkpoint therapy has dramatically changed the therapeutic landscape of solid malignancies. Here, we review the scientific rationale and current data evaluating immune checkpoint inhibitors in acute myeloid leukemia (AML).

Recent Findings: Immune checkpoint inhibitor monotherapy has shown limited clinical activity in AML. Initial results from early-phase clinical trials suggest that rational combinations of immune checkpoint inhibition with hypomethylating agents (HMAs) are safe and potentially more promising. There are currently no data directly comparing immune checkpoint inhibition to standard therapies. Emerging immune targets more specific for leukemia cells including LILRB4 may improve future therapeutic efficacy. The success of immune checkpoint inhibition in AML has been modest to date. However, an improved understanding of the biology and the use of rational combinations has potential to improve rates of durable responses. Multiple clinical trials in AML are currently evaluating the use of immune checkpoints alone and in combination.

Citing Articles

NLRP12/C1qA positive feedback in tumor-associated macrophages regulates immunosuppression through LILRB4/NF-κB pathway in lung adenocarcinoma.

Yin J, Song Y, Fu Y, Wang J, Zhang Z, Ruan S Cancer Immunol Immunother. 2024; 74(1):16.

PMID: 39527158 PMC: 11554950. DOI: 10.1007/s00262-024-03880-6.

Breaking Boundaries: Immunotherapy for Myeloid Malignancies.

Gavrilova T, Schulz E, Mina A Cancers (Basel). 2024; 16(16).

PMID: 39199554 PMC: 11352449. DOI: 10.3390/cancers16162780.

Recent advances in CAR-T therapy for the treatment of acute myeloid leukemia.

Zha C, Song J, Wan M, Lin X, He X, Wu M Ther Adv Hematol. 2024; 15:20406207241263489.

PMID: 39050113 PMC: 11268017. DOI: 10.1177/20406207241263489.

The immunosuppressive landscape in tumor microenvironment.

Liu W, Zhou H, Lai W, Hu C, Xu R, Gu P Immunol Res. 2024; 72(4):566-582.

PMID: 38691319 DOI: 10.1007/s12026-024-09483-8.

Wang J, Wang H, Ding Y, Jiao X, Zhu J, Zhai Z Sci Rep. 2024; 14(1):9115.

PMID: 38643300 PMC: 11032381. DOI: 10.1038/s41598-024-59464-y.

References

Blank C, Brown I, Peterson A, Spiotto M, Iwai Y, Honjo T . PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res. 2004; 64(3):1140-5. DOI: 10.1158/0008-5472.can-03-3259. View

Bleakley M, Riddell S . Molecules and mechanisms of the graft-versus-leukaemia effect. Nat Rev Cancer. 2004; 4(5):371-80. DOI: 10.1038/nrc1365. View

Obeid M, Tesniere A, Ghiringhelli F, Fimia G, Apetoh L, Perfettini J . Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med. 2006; 13(1):54-61. DOI: 10.1038/nm1523. View

Berger R, Rotem-Yehudar R, Slama G, Landes S, Kneller A, Leiba M . Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res. 2008; 14(10):3044-51. DOI: 10.1158/1078-0432.CCR-07-4079. View

Kolb H . Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood. 2008; 112(12):4371-83. DOI: 10.1182/blood-2008-03-077974. View

Zhang L, Gajewski T, Kline J . PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model. Blood. 2009; 114(8):1545-52. PMC: 2731636. DOI: 10.1182/blood-2009-03-206672. View

Dohner H, Estey E, Amadori S, Appelbaum F, Buchner T, Burnett A . Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2009; 115(3):453-74. DOI: 10.1182/blood-2009-07-235358. View

El Kholy N, Sallam M, Ahmed M, Sallam R, Asfour I, Hammouda J . Expression of indoleamine 2,3-dioxygenase in acute myeloid leukemia and the effect of its inhibition on cultured leukemia blast cells. Med Oncol. 2010; 28(1):270-8. DOI: 10.1007/s12032-010-9459-6. View

Almstedt M, Blagitko-Dorfs N, Duque-Afonso J, Karbach J, Pfeifer D, Jager E . The DNA demethylating agent 5-aza-2'-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells. Leuk Res. 2010; 34(7):899-905. DOI: 10.1016/j.leukres.2010.02.004. View

10.

Goodyear O, Agathanggelou A, Novitzky-Basso I, Siddique S, McSkeane T, Ryan G . Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia. Blood. 2010; 116(11):1908-18. DOI: 10.1182/blood-2009-11-249474. View

11.

Zhou Q, Munger M, Highfill S, Tolar J, Weigel B, Riddle M . Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia. Blood. 2010; 116(14):2484-93. PMC: 2953885. DOI: 10.1182/blood-2010-03-275446. View

12.

Kikushige Y, Shima T, Takayanagi S, Urata S, Miyamoto T, Iwasaki H . TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells. Cell Stem Cell. 2010; 7(6):708-17. DOI: 10.1016/j.stem.2010.11.014. View

13.

Zitvogel L, Kepp O, Kroemer G . Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol. 2011; 8(3):151-60. DOI: 10.1038/nrclinonc.2010.223. View

14.

Wemeau M, Kepp O, Tesniere A, Panaretakis T, Flament C, De Botton S . Calreticulin exposure on malignant blasts predicts a cellular anticancer immune response in patients with acute myeloid leukemia. Cell Death Dis. 2011; 1:e104. PMC: 3032293. DOI: 10.1038/cddis.2010.82. View

15.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

16.

Fucikova J, Kralikova P, Fialova A, Brtnicky T, Rob L, Bartunkova J . Human tumor cells killed by anthracyclines induce a tumor-specific immune response. Cancer Res. 2011; 71(14):4821-33. DOI: 10.1158/0008-5472.CAN-11-0950. View

17.

Norde W, Maas F, Hobo W, Korman A, Quigley M, Kester M . PD-1/PD-L1 interactions contribute to functional T-cell impairment in patients who relapse with cancer after allogeneic stem cell transplantation. Cancer Res. 2011; 71(15):5111-22. DOI: 10.1158/0008-5472.CAN-11-0108. View

18.

Galluzzi L, Senovilla L, Zitvogel L, Kroemer G . The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov. 2012; 11(3):215-33. DOI: 10.1038/nrd3626. View

19.

Chen D, Irving B, Hodi F . Molecular pathways: next-generation immunotherapy--inhibiting programmed death-ligand 1 and programmed death-1. Clin Cancer Res. 2012; 18(24):6580-7. DOI: 10.1158/1078-0432.CCR-12-1362. View

20.

Kroemer G, Galluzzi L, Kepp O, Zitvogel L . Immunogenic cell death in cancer therapy. Annu Rev Immunol. 2012; 31:51-72. DOI: 10.1146/annurev-immunol-032712-100008. View